MAY 28, 2015
Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI is an extremely popular momentum indicator that has been featured in a number of articles, interviews and books over the years. In particular, Constance Brown’s book, Technical Analysis for the Trading Professional, features the concept of bull market and bear market ranges for RSI. Andrew Cardwell, Brown’s RSI mentor, introduced positive and negative reversals for RSI. In addition, Cardwell turned the notion of divergence, literally and figuratively, on its head.
RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30. Signals can also be generated by looking for divergences, failure swings and centerline crossovers. RSI can also be used to identify the general trend.
Oncothyreon Inc (USA) (NASDAQ:ONTY) is now in overbought territory with an RSI value of 77.56. The stock is up +106.13% in one month through last close, to $3.36, showing a +108.70% return during the past three months. The share price is up from fifty two week low with +138.30% and low from fifty two week high with -6.67%. It stands +86.65% above the average-price of 50 days and +72.22% compared with the SMA 20.
PPO:18,919 by the sky
ONTY : $ SPX, (Weekly)0.0016 by the sky!!!
A long investor, buying at these levels is suicidal, but the madness runs through the streets of Wall Street these days!
ONTY, in collapse
Any time, again in fallen
Ceres Sprouts Off Patent Awarded For Soybean Seed Enhancement
2:53 pm ET May 27, 2015 (Benzinga)
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
Ceres Inc (NASDAQ: CERE) shares are trading higher by $1.46 at $3.14 in Wednesday's session. The catalyst for the doubling of the agricultural biotechnology company is U.S. patent awarded for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation.
The low-priced volatile issue spiked to the $4 level for the fifth time since March 4, but has not been able to sustain that level for more than one session. That is the case in Wednesday's session as Ceres spike from its low for the day ($1.77) to $4 on the heels of the announcement before retreating to its current level.
It should be noted that other spikes in the issue took place on average volume.
However, the current rally is taking place on much higher than average volume, as 12.3M shares have changed hands compared with its 20-day average of 1M shares with two hours remaining in the session.
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 05/14/2015, 13 days ago, when the stock price was 1,7530. Since then ONTY has risen by +91,67%.
Candlesticks warned us today to be on alert with a new bearish pattern. Market attention is now on the downside.more...
ONTY:Markit short selling activity, It is increasing from low to médium.
ONTY must come down to find your balance in the chart. RSI(14)77.43 Overbought
One thing is cutting jobs and another to shrink the size of the laboratory.
Purchase, honey is rich!
PTIE, Good time to buy!
Do not be fooled, until today no one has discovered the cure for cancer, that is the reality and always rejected the evidence in phase two or three. I've seen a lot of laboratory that finish in chapter eleven, eg, DNDNQ, GNTA, VRML,etc.
Yet on Tuesday CVac seemed to rise from the dead, with Prima revealing that median overall survival - still in the secondary-remitter subgroup - had still not been reached for CVac after 42 months, versus mOS of 25.5 months for placebo. It was not until yesterday that Prima's stock surged - up 167% over Wednesday's close.
The odd thing is that Prima already had basically the same data a year ago at Asco; the only difference is that at that point mOS for CVac had not been reached after 30 months.
For its part, Aveo rose over 100% yesterday before closing up 39%. This followed the group's highlighting of an Asco abstract of a Tivo-1 extension cohort in which the focus was on patients who had progressed after Nexavar and subsequently got tivozanib; these lived for another 21.6 months on average.
Again, there is very little new about this. The extension part did nothing to wipe out the Tivo-1 flop in first-line use, caused by a poor study design whereby geography meant that tivozanib recipients had few follow-up options while most first-line Nexavar failures actually got tivozanib.
Indeed, the Asco abstract reiterated the 18% higher risk of death on tivozanib versus Nexavarin Tivo-1. A likely reason for the sudden surge in investor interest was Aveo's highlighting of an FDA agreement over a Phase III trial design in third-line use.
Still, all this means is that Aveo will have to fund yet another prospective study - to show tivozanib's benefit in a late setting in a highly competitive cancer. Both it and Prima - if the latter is about to resurrect CVac - will surely need to secure partners or some other kind of funding.
Aveo rose another 20% in early trade, while Prima - sitting on a 600% three-day increase on Thursday - slumped by 43% Friday. Investors will certainly try playing the wave of optimism, though given pre- and post-Asco volatility this is not an area for the faint of heart.
End of article.
Happy Holiday, tomorrow
Sentiment: Strong Sell
May 23, 2015 10:54 AM ET(Sheeking Alpha)
When it comes to dead parrots making comebacks it could not have got much more extreme than the severely depressed Aveo Oncology (NASDAQ:AVEO) and Prima Biomed (NASDAQ:PBMD), whose apparently deceased oncology projects suddenly sprung into life this week.
Had they ceased to be or were they just resting? Investors should remain on their guard, especially as closer reading of the disclosures reveals that very little has changed with tivozanib and CVac. Attempts to resurrect these two assets look like little more than a use of pre-Asco biotech fever to raise much-needed cash.
Aveo's tivozanib had been consigned to the scrapheap in renal cell cancer after its Tivo-1 study showed that control-arm patients actually lived longer than those on active treatment, though the primary progression-free survival endpoint was met. A scathing advisory panel was followed by Astellas canning a Europe licensing deal (Adcom double play erases Aveo and Delcath, May 3, 2013).
Prima's CVac - an autologous dendritic cell vaccine bearing a striking similarity to the monumental flop that was Dendreon's (OTCPK:DNDNQ) Provenge - last year flunked an open-label study in 63 epithelial ovarian cancer patients who were in complete remission after first or second-line treatment. CVac missed the primary endpoint of increasing median PFS versus placebo.
At the time, Prima touted a subgroup analysis dredging up a purported positive PFS and overall survival effect in a subgroup of 20 patients who were in second remission, blaming the lack of effect in first remitters on the heterogeneity of this population.
But it then bought the French immuno-oncology group Immutep for $28m and refocused on Immutep's lead asset, IMP321, a MAb against the promising novel inhibitory checkpoint Lag-3. And it threw in the towel with CVac, citing manufacturing complexity and a dwindling patient pool.
AVEO Pharmaceuticals Had $39.1M In Cash Resources As Of March 31 AVEO
6:35 am ET May 07, 2015
AVEO Pharmaceuticals 1Q Rev $134,000 AVEO
AVEO Pharmaceuticals 1Q Loss $10.9M AVEO
6:34 am ET
AVEO Pharmaceuticals 1Q Loss/Shr 21c AVEO
Aveo Pharma Files Up to $100M Debt Securities Shelf
Many short sales activity. Why? The main chart RSI (14) 74.29, Overbought, Is not good.
Fed report does not inspire much confidence. Moreover, until today, no cure for cancer. Make no mistake.